Depatuxizumab, a brain-penetrant, humanized anti-EGFR monoclonal antibody, selectively inhibits the growth of mutant EGFRvIII and wild-type EGFR xenograft models, and is utilized for research on cancer [1].

Losatuxizumab (ABT-806), an anti-EGFR monoclonal antibody, exhibits selective binding affinity towards various EGFR forms, with EC50 values of 0.96 nM for the wild-type EGFR, 0.09 nM for the C271A,C283A mutant, 0.12 nM for EGFRvIII, and 0.66 nM for EGFR1-501. It is utilized in research targeting EGFR-expressing cancers [1] [2].